An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs Mocetinostat (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Proof of concept; Therapeutic Use
- 05 Apr 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 05 Apr 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.
- 05 Apr 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.